Breakthroughs in Solubility Optimization for Pediatric Drug Formulations
Main Article Content
Abstract
Formulating drugs for pediatric patients is more complex than for adults due to the diversity within this group. Solubility of active pharmaceutical ingredients (APIs) presents specific challenges, since children have unique physiological traits—smaller stomach volume and immature digestive systems—that affect absorption, metabolism, and overall drug effectiveness.
Oral formulations must consider drug sensitivity, swallowing difficulties, and compliance. Taste, ease of administration, and patient acceptance strongly influence therapeutic outcomes and safety. Ensuring children take medication as directed is often as important as the formulation itself.
To address these issues, solubility enhancement technologies have advanced
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1- Malkawi WA, AlRafayah E, AlHazabreh M, AbuLaila S, Al-Ghananeem AM. Formulation challenges and strategies to develop pediatric dosage forms. Children. 2022 Apr 1;9(4).Pp:488.
2-Sura Zuhair M, Nora Zawar Y, Zeina Dawood S.Types of Attractive Dosage Forms for Primary School Students and Associated Factors in Baghdad/ Iraq.Al Mustansiriyah Journal of Pharmaceutical Sciences.2022.20(4).Pp:13-22.
3-Lopez FL, Ernest TB, Tuleu C, Gul MO.Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.Expert Opin Drug Deliv.2015.12(11).Pp:1727-40. DOI: https://doi.org/10.1517/17425247.2015.1060218
4-Dille MJ, Hattrem MN, Draget KI.Soft, chewable gelatin-based pharmaceutical oral formulations: a technical approach.Pharm Dev Technol.2018.23(5).Pp:504-11. DOI: https://doi.org/10.1080/10837450.2017.1332642
5-Rose K, Van den Anker JN. Guide to paediatric drug development and clinical research: Karger Medical and Scientific Publishers; 2010. DOI: https://doi.org/10.1159/isbn.978-3-8055-9363-2
6-Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD.Pediatric information in drug product labeling.JAMA.2012.307(18).Pp:1914-5. DOI: https://doi.org/10.1001/jama.2012.3435
7-Denora N, Lopalco A. Paediatric Formulation: Design and Development: MDPI; 2021. DOI: https://doi.org/10.3390/ijms21197118
8- Jacqz-Aigrain E. Drug policy in Europe: research and funding in neonates: current challenges, future perspectives, new opportunities. Early human development. 2011 Mar 1;87:S27-30.
9-Serrano DR, Kara A, Yuste I, Luciano FC, Ongoren B, Anaya BJ, et al.3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals.Pharmaceutics.2023.15(2).Pp: DOI: https://doi.org/10.3390/pharmaceutics15020313
10-Meyers RS.The Past, Present, and Future of Oral Dosage Forms for Children.J Pediatr Pharmacol Ther.2024.29(1).Pp:22-31. DOI: https://doi.org/10.5863/1551-6776-29.1.22
11-Nunn T, Williams J.Formulation of medicines for children.Br J Clin Pharmacol.2005.59(6).Pp:674-6. DOI: https://doi.org/10.1111/j.1365-2125.2005.02410.x
12- Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Frontiers in pharmacology. 2021 Feb 19;12:618411. DOI: https://doi.org/10.3389/fphar.2021.618411
13-Kim J, De Jesus O. Medication Routes of Administration: StatPearls Publishing, Treasure Island (FL); 2023.
14-Lou J, Duan H, Qin Q, Teng Z, Gan F, Zhou X, et al.Advances in Oral Drug Delivery Systems: Challenges and Opportunities.Pharmaceutics.2023.15(2).Pp:484. DOI: https://doi.org/10.3390/pharmaceutics15020484
15-Montgomery RK, Grand RJ. Development of the gastrointestinal tract. Pediatric Gastrointestinal and Liver Disease: Elsevier; 2011. p. 2-9. e2. DOI: https://doi.org/10.1016/B978-1-4377-0774-8.10001-6
16-Mistry P, Batchelor H, project SP-U.Evidence of acceptability of oral paediatric medicines: a review.J Pharm Pharmacol.2017.69(4).Pp:361-76. DOI: https://doi.org/10.1111/jphp.12610
17-Ricci BM.Bridging studies in support of oral pediatric formulation development.Int J Pharm.2013.457(1).Pp:323-6. DOI: https://doi.org/10.1016/j.ijpharm.2013.07.074
18-Ward RM, Benjamin D, Barrett JS, Allegaert K, Portman R, Davis JM, et al.Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.Pediatr Res.2017.81(5).Pp:692-711. DOI: https://doi.org/10.1038/pr.2016.221
19- Committee for Medicinal Products for Human Use. Guideline on pharmaceutical development of medicines for pediatric use. European Medicines Agency Scientific Guidelines. Accessed. 2018 Jul;15.
20-Sam T, Ernest TB, Walsh J, Williams JL.A benefit/risk approach towards selecting appropriate pharmaceutical dosage forms - an application for paediatric dosage form selection.Int J Pharm.2012.435(2).Pp:115-23. DOI: https://doi.org/10.1016/j.ijpharm.2012.05.024
21-Natalie S, Viviane K, Ines S, Christian L, Thomas M, Jörg B.Acceptance of drug-free minitablets in young children.
22-Litalien C, Berube S, Tuleu C, Gilpin A, Landry EK, Valentin M, et al.From paediatric formulations development to access: Advances made and remaining challenges.Br J Clin Pharmacol.2022.88(10).Pp:4349-83.
23-Litalien C, Bérubé S, Tuleu C, Gilpin A, Landry É K, Valentin M, et al.From paediatric formulations development to access: Advances made and remaining challenges.Br J Clin Pharmacol.2022.88(10).Pp:4349-83. DOI: https://doi.org/10.1111/bcp.15293
24-Kristensen HG.WHO guideline development of paediatric medicines: points to consider in pharmaceutical development.Int J Pharm.2012.435(2).Pp:134-5. DOI: https://doi.org/10.1016/j.ijpharm.2012.05.054
25-Krause J, Breitkreutz J.Improving Drug Delivery in Paediatric Medicine.Pharmaceutical Medicine.2008.22(1).Pp:41-50. DOI: https://doi.org/10.1007/BF03256681
26-Galande AD, Khurana NA, Mutalik SJJoAPS.Pediatric dosage forms-challenges and recent developments: A critical review.2020.10(7).Pp:155-66. DOI: https://doi.org/10.7324/JAPS.2020.10718
27- Committee for Medicinal Products for Human Use. Formulations of choice for the paediatric population. European Medicines Agency. 2005.
28-Venables R, Stirling H, Batchelor H, Marriott J.Problems with oral formulations prescribed to children: a focus group study of healthcare professionals.Int J Clin Pharm.2015.37(6).Pp:1057-67. DOI: https://doi.org/10.1007/s11096-015-0152-x
29-Malkawi WA, AlRafayah E, AlHazabreh M, AbuLaila S, Al-Ghananeem AM.Formulation Challenges and Strategies to Develop Pediatric Dosage Forms.Children (Basel).2022.9(4).Pp:488. DOI: https://doi.org/10.3390/children9040488
30- Jacqz-Aigrain E. Drug policy in Europe: research and funding in neonates: current challenges, future perspectives, new opportunities. Early human development. 2011 Mar 1;87:S27-30. DOI: https://doi.org/10.1016/j.earlhumdev.2011.01.007
31-Broussard L.Small size, big risk: preventing neonatal and pediatric medication errors.Nurs Womens Health.2010.14(5).Pp:405-8. DOI: https://doi.org/10.1111/j.1751-486X.2010.01580.x
32-Wening K, Breitkreutz J.Oral drug delivery in personalized medicine: unmet needs and novel approaches.Int J Pharm.2011.404(1-2).Pp:1-9. DOI: https://doi.org/10.1016/j.ijpharm.2010.11.001
33-Donnell C, Nunn T.How to manipulate drugs so they can be given to children.Nurs Child Young People.2011.23(4).Pp:6-7. DOI: https://doi.org/10.7748/ncyp2011.05.23.4.6.p5165
34-Rei Bolislis W, Bejeuhr G, Benzaghou F, Corriol-Rohou S, Herrero-Martinez E, Hildebrand H, et al.Optimizing Pediatric Medicine Developments in the European Union Through Pragmatic Approaches.Clin Pharmacol Ther.2021.110(4).Pp:871-9. DOI: https://doi.org/10.1002/cpt.2152
35-Rosen Y, Gurman P, Elman N. Navigating the FDA Regulatory Processes: An Integrated Clinical and Engineering Approach: CRC Press; 2025. DOI: https://doi.org/10.1201/9781315117911
36-Walsh J, Bickmann D, Breitkreutz J, Chariot-Goulet M, European Paediatric Formulation I.Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments.Int J Pharm.2011.415(1-2).Pp:221-31. DOI: https://doi.org/10.1016/j.ijpharm.2011.05.048
37-Batchelor HK, Marriott JF.Formulations for children: problems and solutions.Br J Clin Pharmacol.2015.79(3).Pp:405-18. DOI: https://doi.org/10.1111/bcp.12268
38- Kapoor DU, Garg R, Gaur M, Patel MB, Minglani VV, Prajapati BG, Huanbutta K, Sangnim T, Sriamornsak P. Pediatric drug delivery challenges: enhancing compliance through age-appropriate formulations and safety measures. Journal of Drug Delivery Science and Technology. 2024 Apr 26:105720. DOI: https://doi.org/10.1016/j.jddst.2024.105720
39- Deng Y, Shen L, Yang Y, Shen J. Development of nanoparticle-based orodispersible palatable pediatric formulations. International journal of pharmaceutics. 2021 Mar 1;596:120206. DOI: https://doi.org/10.1016/j.ijpharm.2021.120206
40-Lafeber I, Ruijgrok EJ, Guchelaar HJ, Schimmel KJ. 3D printing of pediatric medication: the end of bad tasting oral liquids?—a scoping review. Pharmaceutics. 2022 Feb 14;14(2):416. DOI: https://doi.org/10.3390/pharmaceutics14020416
41-Kennedy AR, Massey LR.Pediatric medication safety considerations for pharmacists in an adult hospital setting.Am J Health Syst Pharm.2019.76(19).Pp:1481-91. DOI: https://doi.org/10.1093/ajhp/zxz168
42-Raynor DK, De Veene P, Bryant D.The Effectiveness of the Summary of Product Characteristics (SmPC) and Recommendations for Improvement.Therapeutic Innovation & Regulatory Science.2014.48(2).Pp:255-65. DOI: https://doi.org/10.1177/2168479013501311
43-Zuccari G, Alfei S, Marimpietri D, Iurilli V, Barabino P, Marchitto L.Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics.Pharmaceuticals (Basel).2022.15(1).Pp:108. DOI: https://doi.org/10.3390/ph15010108
44 Mfoafo KA, Omidian M, Bertol CD, Omidi Y, Omidian H. Neonatal and pediatric oral drug delivery: Hopes and hurdles. International Journal of Pharmaceutics. 2021 Mar 15;597:120296. DOI: https://doi.org/10.1016/j.ijpharm.2021.120296
45-Khalaf YT, Almajidi YQ, Shalan NM, Alani IH, Dayyih WAA.Preparation and Evaluation of Oroslippery Tablets Contain Irbesartan and Hydrochlorothiazide Combination.
46-Jain KK.An Overview of Drug Delivery Systems.Methods Mol Biol.2020.2059(1-54. DOI: https://doi.org/10.1007/978-1-4939-9798-5_1
47-Belayneh A, Tadese E, Molla FJIJoGM.Safety and biopharmaceutical challenges of excipients in off-label pediatric formulations.2020.1051-66.
48-Domingues C, Jarak I, Veiga F, Dourado M, Figueiras A.Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.Pharmaceutics.2023.15(10).Pp:2431. DOI: https://doi.org/10.3390/pharmaceutics15102431
49- Khong YM, Liu J, Cook J, Purohit V, Thompson K, Mehrotra S, Cheung SA, Hay JL, Fletcher EP, Wang J, Sachs HC. Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019. European journal of pharmaceutics and biopharmaceutics. 2021 Jul 1;164:66-74. DOI: https://doi.org/10.1016/j.ejpb.2021.04.010
50-Bensid A, El Abed N, Houicher A, Regenstein JM, Özogul F.Antioxidant and antimicrobial preservatives: Properties, mechanism of action and applications in food - a review.Crit Rev Food Sci Nutr.2022.62(11).Pp:2985-3001. DOI: https://doi.org/10.1080/10408398.2020.1862046
51-Ivanovska V, Rademaker CM, van Dijk L, Mantel-Teeuwisse AK.Pediatric drug formulations: a review of challenges and progress.Pediatrics.2014.134(2).Pp:361-72. DOI: https://doi.org/10.1542/peds.2013-3225
52-Rouaz K, Chiclana-Rodriguez B, Nardi-Ricart A, Sune-Pou M, Mercade-Frutos D, Sune-Negre JM, et al.Excipients in the Paediatric Population: A Review.Pharmaceutics.2021.13(3).Pp:387. DOI: https://doi.org/10.3390/pharmaceutics13030387
53-Nankar M, Walimbe H, Ahmed Bijle MN, Kontham U, Kamath A, Muchandi S.Comparative evaluation of cariogenic and erosive potential of commonly prescribed pediatric liquid medicaments: an in vitro study.J Contemp Dent Pract.2014.15(1).Pp:20-5. DOI: https://doi.org/10.5005/jp-journals-10024-1481
54-Attebäck M, Hedin B, Mattsson S.Formulation Optimization of Extemporaneous Oral Liquids Containing Naloxone and Propranolol for Pediatric Use.2022.90(1).Pp:15. DOI: https://doi.org/10.3390/scipharm90010015
55-Saadallah MN, Almajidi YQ, Ali AJA-RJoMS.Binary Ethosomal Gel for Enhanced Transdermal Delivery of Tazarotene: Development, Refinement, in vitro Evaluation, and Skin Penetration Investigations.2023.5(1S).Pp:S42-50. DOI: https://doi.org/10.54133/ajms.v5i1S.288
56- Gleeson JP, Fein KC, Whitehead KA. Oral delivery of peptide therapeutics in infants: Challenges and opportunities. Advanced drug delivery reviews. 2021 Mar 25;173:112. DOI: https://doi.org/10.1016/j.addr.2021.03.011
57- Abdelhakim HE, Coupe A, Tuleu C, Edirisinghe M, Craig DQ. Utilising co-axial electrospinning as a taste-masking technology for paediatric drug delivery. Pharmaceutics. 2021 Oct 12;13(10):1665. DOI: https://doi.org/10.3390/pharmaceutics13101665
58-Musakhanian J, Rodier JD, Dave M.Oxidative Stability in Lipid Formulations: a Review of the Mechanisms, Drivers, and Inhibitors of Oxidation.AAPS PharmSciTech.2022.23(5).Pp:151. DOI: https://doi.org/10.1208/s12249-022-02282-0
59- Ioniuc IK, Lupu A, Dragan F, Tarnita I, Alexoae MM, Streanga V, Mitrofan C, Thet AA, Nedelcu AH, Salaru DL, Burlea SL. Oxidative stress and antioxidants in pediatric asthma’s evolution and management. Antioxidants. 2024 Oct 31;13(11):1331. DOI: https://doi.org/10.3390/antiox13111331
60-Vangara KK, Yellepeddi VK. Excipients in Pediatric Formulations: Biopharmaceutical and Toxicological Considerations. In: Narang AS, Boddu SHS, editors. Excipient Applications in Formulation Design and Drug Delivery. Cham: Springer International Publishing; 2015. p. 497-519. DOI: https://doi.org/10.1007/978-3-319-20206-8_16
61-Mora MR, Dando R.The sensory properties and metabolic impact of natural and synthetic sweeteners.Compr Rev Food Sci Food Saf.2021.20(2).Pp:1554-83. DOI: https://doi.org/10.1111/1541-4337.12703
62-Gasmi Benahmed A, Gasmi A, Arshad M, Shanaida M, Lysiuk R, Peana M, et al.Health benefits of xylitol.Appl Microbiol Biotechnol.2020.104(17).Pp:7225-37. DOI: https://doi.org/10.1007/s00253-020-10708-7
63-Hu J, Fitaihi R, Abukhamees S, Abdelhakim HE.Formulation and Characterisation of Carbamazepine Orodispersible 3D-Printed Mini-Tablets for Paediatric Use.Pharmaceutics.2023.15(1).Pp:250. DOI: https://doi.org/10.3390/pharmaceutics15010250
64-Orlu M, Salunke S, Tuleu C.Paediatric pharmaceutics—the science of formulating medicines for children.2018. DOI: https://doi.org/10.1039/9781782620402-00258
65-Narang AS, Boddu SH. Excipient Applications in Formulation Design and Drug Delivery. In: Narang AS, Boddu SHS, editors. Excipient Applications in Formulation Design and Drug Delivery; Cham: Springer International Publishing; 2015. p. 1-10. DOI: https://doi.org/10.1007/978-3-319-20206-8_1
66-Suksawat T, Brniak W, Łyszczarz E, Wesoły M, Ciosek-Skibińska P, Mendyk A. Orodispersible dosage forms with rhinacanthin-rich extract as a convenient formulation dedicated to pediatric patients. Pharmaceuticals. 2024 Jul 27;17(8):994. DOI: https://doi.org/10.3390/ph17080994
67-Bhalani DV, Nutan B, Kumar A, Singh Chandel AKJB.Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics.2022.10(9).Pp:2055. DOI: https://doi.org/10.3390/biomedicines10092055
68-Kriegel C, Festag M, Kishore RSK, Roethlisberger D, Schmitt G.Pediatric Safety of Polysorbates in Drug Formulations.Children (Basel).2019.7(1).Pp:1. DOI: https://doi.org/10.3390/children7010001
69-Bobillot M, Delannoy V, Trouillard A, Kinowski JM, Sanchez-Ballester NM, Soulairol I.Potentially Harmful Excipients: State of the Art for Oral Liquid Forms Used in Neonatology and Pediatrics Units.Pharmaceutics.2024.16(1).Pp:119. DOI: https://doi.org/10.3390/pharmaceutics16010119
70-Hoffman AC, Salgado RV, Dresler C, Faller RW, Bartlett CJTc.Flavour preferences in youth versus adults: a review.2016.25(Suppl 2).Pp:ii32-ii9. DOI: https://doi.org/10.1136/tobaccocontrol-2016-053192
71-Golhen K, Buettcher M, Kost J, Huwyler J, Pfister M.Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children.Pharmaceutics.2023.15(4).Pp:1033. DOI: https://doi.org/10.3390/pharmaceutics15041033
72-Pereira M, Silva FC, Simões S, Ribeiro HM, Almeida AJ, Marto J.Innovative, Sugar-Free Oral Hydrogel as a Co-administrative Vehicle for Pediatrics: a Strategy to Enhance Patient Compliance.AAPS PharmSciTech.2022.23(4).Pp:107. DOI: https://doi.org/10.1208/s12249-022-02265-1
73-Belayneh A, Tadese E, Molla F.Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations.Int J Gen Med.2020.13(1051-66. DOI: https://doi.org/10.2147/IJGM.S280330
74- Pezik E, Gulsun T, Sahin S, Vural I. Development and characterization of pullulan-based orally disintegrating films containing amlodipine besylate. European Journal of Pharmaceutical Sciences. 2021 Jan 1;156:105597. DOI: https://doi.org/10.1016/j.ejps.2020.105597
75-Wang K, Jiang K, Wei X, Li Y, Wang T, Song Y.Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.AAPS PharmSciTech.2021.22(6).Pp:208. DOI: https://doi.org/10.1208/s12249-021-02076-w
76-Vallabh M. Evaluation of Salivary pH, Flow Rate and Buffer Capacity in Children with Protein Energy Malnutrition-A Comparative Study: Rajiv Gandhi University of Health Sciences (India); 2016.
77-Hidas A, Noy AF, Birman N, Shapira J, Matot I, Steinberg D, et al.Oral health status, salivary flow rate and salivary quality in children, adolescents and young adults with ADHD.Arch Oral Biol.2011.56(10).Pp:1137-41. DOI: https://doi.org/10.1016/j.archoralbio.2011.03.018
78-Kaguelidou F, Kassai Koupai B, Durrieu G.Pediatric pharmacology.Therapie.2018.73(2).Pp:111-2. DOI: https://doi.org/10.1016/j.therap.2018.02.003
79-LUSCOMBE DK, NICHOLLS PJ. Processes of drug handling by the body. Smith and Williams' Introduction to the Principles of Drug Design and Action: CRC Press; 2019. p. 1-27. DOI: https://doi.org/10.1201/9781315273792-1
80-Chapron BD, Chapron A, Leeder JS.Recent advances in the ontogeny of drug disposition.Br J Clin Pharmacol.2022.88(10).Pp:4267-84. DOI: https://doi.org/10.1111/bcp.14821
81-Juárez-Hernández JE, Carleton BC.Paediatric oral formulations: Why don't our kids have the medicines they need?Br J Clin Pharmacol.2022.88(10).Pp:4337-48. DOI: https://doi.org/10.1111/bcp.15456
82-Pildes RS, Blumenthal I, Ebel A.Stomach emptying in the newborn.Pediatrics.1980.66(3).Pp:482-3. DOI: https://doi.org/10.1542/peds.66.3.482a
83- Mehta V, Hopson PE, Smadi Y, Patel SB, Horvath K, Mehta DI. Development of the human pancreas and its exocrine function. Frontiers in pediatrics. 2022 Sep 29;10:909648. DOI: https://doi.org/10.3389/fped.2022.909648
84-McNamara PJ, Alcorn J.Protein binding predictions in infants.AAPS PharmSci.2002.4(1).Pp:E4. DOI: https://doi.org/10.1208/ps040104
85-Talevi A, Bellera CL. Drug Binding to Tissue Components. The ADME Encyclopedia; Cham: Springer International Publishing; 2021. p. 1-9. DOI: https://doi.org/10.1007/978-3-030-51519-5_57-1
86- Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clinical pharmacokinetics. 2015 Dec;54:1183-204. DOI: https://doi.org/10.1007/s40262-015-0298-7
87- Mura P, Maestrelli F, D’Ambrosio M, Luceri C, Cirri M. Evaluation and comparison of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as vectors to develop hydrochlorothiazide effective and safe pediatric oral liquid formulations. Pharmaceutics. 2021 Mar 24;13(4):437. DOI: https://doi.org/10.3390/pharmaceutics13040437
88-Ogbonna JDN, Cunha E, Attama AA, Ofokansi KC, Ferreira H, Pinto S, et al.Overcoming Challenges in Pediatric Formulation with a Patient-Centric Design Approach: A Proof-of-Concept Study on the Design of an Oral Solution of a Bitter Drug.Pharmaceuticals (Basel).2022.15(11).Pp:1331. DOI: https://doi.org/10.3390/ph15111331
89-Langer C, Diaz DA, Van Alstine L, Bandi N, Fitzgerald S, Colgan S.Analysis of the Regulatory Divergence of Comparative Dissolution Requirements for Post-Approval Manufacturing Changes of Modified Release Solid Oral Dosage Forms.AAPS J.2019.22(1).Pp:2. DOI: https://doi.org/10.1208/s12248-019-0383-1
90- Tan DC, Khong YM, Mount S, Galella E, Mitra B, Charlton S, Kuhli M, Ternik R, Walsh J, Rajapakshe A, Thompson K. Pediatric formulation development–Challenges of today and strategies for tomorrow: Summary report from M− CERSI workshop 2019. European Journal of Pharmaceutics and Biopharmaceutics. 2021 Jul 1;164:54-65. DOI: https://doi.org/10.1016/j.ejpb.2021.04.011
91- Cheung SY, Hay JL, Lin YW, de Greef R, Bullock J. Pediatric oncology drug development and dosage optimization. Frontiers in Oncology. 2024 Jan 29;13:1235947. DOI: https://doi.org/10.3389/fonc.2023.1235947
92-Chiaruttini G, Felisi M, Bonifazi DJTMoCTRI.Challenges in paediatric clinical trials: How to Make It Feasible.2018.Pp:11-33. DOI: https://doi.org/10.5772/intechopen.72950
93-Shonkoff JP, Richter L, Van Der Gaag J, Bhutta ZAJP.An integrated scientific framework for child survival and early childhood development.2012.129(2).Pp:e460-e72. DOI: https://doi.org/10.1542/peds.2011-0366
94- Khan D, Kirby D, Bryson S, Shah M, Mohammed AR. Paediatric specific dosage forms: Patient and formulation considerations. International journal of pharmaceutics. 2022 Mar 25;616:121501. DOI: https://doi.org/10.1016/j.ijpharm.2022.121501
95-Mahmood SZ, Yousif NZ, Salman ZDJAMJoPS.Types of Attractive Dosage Forms for Primary School Students and Associated Factors in Baghdad/Iraq.2020.20(4).Pp:13-22. DOI: https://doi.org/10.32947/ajps.v20i4.770
96-Almajidi YQ, Albadri AA, Jwaid MMJMJfMS.Utilization of semiconductor nanocrystals in cancer diagnose and treatment.2023.2(4).Pp:5. DOI: https://doi.org/10.55810/2789-9136.1034
97-Ernest TB, Craig J, Nunn A, Salunke S, Tuleu C, Breitkreutz J, et al.Preparation of medicines for children - a hierarchy of classification.Int J Pharm.2012.435(2).Pp:124-30. DOI: https://doi.org/10.1016/j.ijpharm.2012.05.070
98-Richey RH, Craig JV, Shah UU, Ford JL, Barker CE, Peak M, et al.The manipulation of drugs to obtain the required dose: systematic review.J Adv Nurs.2012.68(9).Pp:2103-12. DOI: https://doi.org/10.1111/j.1365-2648.2011.05916.x
99-Fabiano V, Mameli C, Zuccotti GV.Paediatric pharmacology: remember the excipients.Pharmacol Res.2011.63(5).Pp:362-5. DOI: https://doi.org/10.1016/j.phrs.2011.01.006
100-Baguley D, Lim E, Bevan A, Pallet A, Faust SN.Prescribing for children - taste and palatability affect adherence to antibiotics: a review.Arch Dis Child.2012.97(3).Pp:293-7. DOI: https://doi.org/10.1136/archdischild-2011-300909
101-Hu S, Liu X, Zhang S, Quan D.An Overview of Taste-Masking Technologies: Approaches, Application, and Assessment Methods.AAPS PharmSciTech.2023.24(2).Pp:67. DOI: https://doi.org/10.1208/s12249-023-02520-z
102- Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clinical pharmacokinetics. 2014 Apr;53:327-46. DOI: https://doi.org/10.1007/s40262-014-0134-5
103-Ryu GS, Lee YJ.Analysis of liquid medication dose errors made by patients and caregivers using alternative measuring devices.J Manag Care Pharm.2012.18(6).Pp:439-45. DOI: https://doi.org/10.18553/jmcp.2012.18.6.439
104-Yin HS, Mendelsohn AL, Wolf MS, Parker RM, Fierman A, van Schaick L, et al.Parents' medication administration errors: role of dosing instruments and health literacy.Arch Pediatr Adolesc Med.2010.164(2).Pp:181-6. DOI: https://doi.org/10.1001/archpediatrics.2009.269
105-Sosnik A, Seremeta KP, Imperiale JC, Chiappetta DA.Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases.Expert Opin Drug Deliv.2012.9(3).Pp:303-23. DOI: https://doi.org/10.1517/17425247.2012.655268
106- World Health Organization. Development of paediatric medicines: points to consider in formulation. WHO technical report series. 2012;790.
107-Hill SR.Putting the priorities first: medicines for maternal and child health.Bull World Health Organ.2012.90(3).Pp:236-8. DOI: https://doi.org/10.2471/BLT.11.088658
108-Liu F, Ranmal S, Batchelor HK, Orlu-Gul M, Ernest TB, Thomas IW, et al.Formulation factors affecting acceptability of oral medicines in children.Int J Pharm.2015.492(1-2).Pp:341-3. DOI: https://doi.org/10.1016/j.ijpharm.2015.05.013
109- Vlad RA, Antonoaea P, Todoran N, Rédai EM, Bîrsan M, Muntean DL, Imre S, Hancu G, Farczádi L, Ciurba A. Development and evaluation of cannabidiol orodispersible tablets using a 23-factorial design. Pharmaceutics. 2022 Jul 14;14(7):1467. DOI: https://doi.org/10.3390/pharmaceutics14071467
110-Wang B, Yang L, Wang B, Luo C, Wang Y, Wang H, et al.Development, In Vitro and In Vivo Evaluation of Racecadotril Orodispersible Films for Pediatric Use.AAPS PharmSciTech.2021.22(1).Pp:15. DOI: https://doi.org/10.1208/s12249-020-01896-6
111- Patel H, Raje V, Maczko P, Patel K. Application of 3D printing technology for the development of dose adjustable geriatric and pediatric formulation of celecoxib. International Journal of Pharmaceutics. 2024 Apr 25;655:123941. DOI: https://doi.org/10.1016/j.ijpharm.2024.123941
112-Purandare S, Khot S, Avachat A."Fabrication of pellets via extrusion-spheronization for engineered delivery of Famotidine through specialized straws for Paediatrics".Ann Pharm Fr.2024.82(2).Pp:271-84. DOI: https://doi.org/10.1016/j.pharma.2023.12.008
113-Chachlioutaki K, Iordanopoulou A, Bouropoulos N, Meikopoulos T, Gika H, Ritzoulis C, et al.Pediatric and Geriatric-Friendly Buccal Foams: Enhancing Omeprazole Delivery for Patients Encountering Swallowing Difficulties.J Pharm Sci.2023.112(10).Pp:2644-54. DOI: https://doi.org/10.1016/j.xphs.2023.07.025
114-Singh D, Bedi N, Tiwary AK.Enhancing solubility of poorly aqueous soluble drugs: critical appraisal of techniques.Journal of Pharmaceutical Investigation.2017.48(5).Pp:509-26. DOI: https://doi.org/10.1007/s40005-017-0357-1
115- Salunke S, O'Brien F, Tan DC, Harris D, Math MC, Ariën T, Klein S, Timpe C. Oral drug delivery strategies for development of poorly water soluble drugs in paediatric patient population. Advanced Drug Delivery Reviews. 2022 Nov 1;190:114507. DOI: https://doi.org/10.1016/j.addr.2022.114507
116- Frodsham M, Penton JA, inventors; Therakind Ltd, assignee. Methotrexate formulation. United States patent US 11,129,833. 2021 Sep 28.
117-Rautio J. Prodrugs. In: Offermanns S, Rosenthal W, editors. Encyclopedia of Molecular Pharmacology; Cham: Springer International Publishing; 2021. Pp:1257-63. DOI: https://doi.org/10.1007/978-3-030-57401-7_10065
118-Franck B, Woillard JB, Theoret Y, Bittencourt H, Demers E, Briand A, et al.Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.Br J Clin Pharmacol.2021.87(8).Pp:3105-14. DOI: https://doi.org/10.1111/bcp.14719
119-He M, Zheng W, Wang N, Gao H, Ouyang D, Huang Z.Molecular Dynamics Simulation of Drug Solubilization Behavior in Surfactant and Cosolvent Injections.Pharmaceutics.2022.14(11).Pp:2366. DOI: https://doi.org/10.3390/pharmaceutics14112366
120-Polymersomes as Novel Drug Delivery Alternative to Conventional Liposomes.Al Mustansiriyah Journal of Pharmaceutical Sciences.2025.24(4).Pp:396-408. DOI: https://doi.org/10.32947/ajps.v24i4.955
121-Bedogni G, Garcia P, Seremeta K, Okulik N, Salomon C.Preformulation and Long-Term Stability Studies of an Optimized Palatable Praziquantel Ethanol-Free Solution for Pediatric Delivery.Pharmaceutics.2023.15(8).Pp:2050. DOI: https://doi.org/10.3390/pharmaceutics15082050
122-Pokhrel DR, Sah MK, Gautam B, Basak HK, Bhattarai A, Chatterjee A.A recent overview of surfactant-drug interactions and their importance.RSC Adv.2023.13(26).Pp:17685-704. DOI: https://doi.org/10.1039/D3RA02883F
123-Elbardisy B, Boraie N, Galal S.Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization.Pharmaceutics.2022.14(12).Pp:2717. DOI: https://doi.org/10.3390/pharmaceutics14122717
124-Qasim Almajidi Y, Jawad AQ, Abdulameer Albadri A.Biocompatible PAMAM-PLGA-PCL Nanocarrier for Efficient Curcumin Delivery to Lung Cancer Cells: In Vitro Studies.Chem Biodivers.2024.21(10).Pp:e202401106. DOI: https://doi.org/10.1002/cbdv.202401106
125-Dahash RA, Rajab NA, Almajidi YQJIJDDT.Investigation of the effect of variable components on the preparation and in-vitro evaluation of lacidipine as an oral nanoemulsion dosage form.2021.11(3).Pp:1031-6.
126-Pınar SG, Oktay AN, Karaküçük AE, Çelebi N.Formulation Strategies of Nanosuspensions for Various Administration Routes.Pharmaceutics.2023 May 17;15(5) Pp:1520. DOI: https://doi.org/10.3390/pharmaceutics15051520
127-Perween N, Alshehri S, Easwari T, Verma V, Faiyazuddin M, Alanazi A, et al.Investigating the feasibility of mefenamic acid nanosuspension for pediatric delivery: Preparation, characterization, and role of excipients.2021.9(4).Pp:574. DOI: https://doi.org/10.3390/pr9040574
128-Cirri M, Maestrelli F, Mennini N, Mannelli LD, Micheli L, Ghelardini C, Mura P. Development of a stable oral pediatric solution of hydrochlorothiazide by the combined use of cyclodextrins and hydrophilic polymers. International Journal of Pharmaceutics. 2020 Sep 25;587. Pp:119692. DOI: https://doi.org/10.1016/j.ijpharm.2020.119692
129-Cirri M, Mura P, Benedetti S, Buratti S.Development of a Hydroxypropyl-beta-Cyclodextrin-Based Liquid Formulation for the Oral Administration of Propranolol in Pediatric Therapy.Pharmaceutics.2023.15(9).Pp:2217. DOI: https://doi.org/10.3390/pharmaceutics15092217
130- Hashim GM, Hameed GS, Hanna DB. The possible techniques that used to improve the bioavailablity, pharmacological activity, solubility and permeability of anti-viral drugs: Insight for COVID-19 antiviral drugs. AJPS. 2023 Jul 20;Pp:231. DOI: https://doi.org/10.32947/ajps.v23i3.1040
131- Virtanen AA, Myślińska M, Healy AM, Power E, Madi A, Sivén M. The challenge of downstream processing of spray dried amorphous solid dispersions into minitablets designed for the paediatric population–A sustainable product development approach. European Journal of Pharmaceutical Sciences. 2024 May 1;196. Pp:106752. DOI: https://doi.org/10.1016/j.ejps.2024.106752
132-Frenck RW, Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al.Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.N Engl J Med.2021.385(3).Pp:239-50. DOI: https://doi.org/10.1056/NEJMoa2107456
133-Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al.Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med.2018.378(5).Pp:439-48.
134-Luo S, Ran M, Luo Q, Shu M, Guo Q, Zhu Y, et al.Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial.Paediatr Drugs.2017.19(5).Pp:479-86. DOI: https://doi.org/10.1007/s40272-017-0237-1
135- Płoszczuk A, Bosheva M, Spooner K, McIver T, Dissanayake S. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial. Therapeutic advances in respiratory disease. 2018 May 31;12:1753466618777924. DOI: https://doi.org/10.1177/1753466618777924
136-Schwartz S, Correll CU.Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.J Am Acad Child Adolesc Psychiatry.2014.53(2).Pp:174-87. DOI: https://doi.org/10.1016/j.jaac.2013.11.005
137- Almajidi YQ, Muslim RK. Oligonucleotides as a Novel Therapeutic Approach: An Innovative Area for Drug Delivery in Neurological Disorders. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2025 Jan 14;25(1).Pp:143-69. DOI: https://doi.org/10.32947/ajps.v25i1.1065
138-de Figueiredo ACM. Real-world effectiveness of gene therapy Zolgensma®(Onasemnogene Abeparvovec-xioi) for the treatment of Spinal Muscular Atrophy (SMA): Universidade de Lisboa (Portugal); 2021.
139-Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, et al.Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.J Clin Endocrinol Metab.2022.107(7).Pp:e2717-e28. DOI: https://doi.org/10.1210/clinem/dgac220